Dry powder inhaler
US9415008B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 20, 2016 |
| Grant date | Aug 16, 2016 |
| Priority date | — |
| Expiry date | Jan 20, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M2202/064
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 μg; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 μg; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.